Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

Rhea-AI Summary

Market Context

CARL's 4.14% pre-publication gain contrasted with mixed peer moves, including NRC at -1.57% and SY a...

Analysis

CARL's 4.14% pre-publication gain contrasted with mixed peer moves, including NRC at -1.57% and SY at +5.02%; the available market data did not establish a sector-wide comparison for the lawsuit.

Key Figures

Patents in complaint: Eight patents

Patents in complaint

Eight patents

Patent infringement lawsuit against DeGen Medical

Key Terms

patent infringement lawsuit, injunctive relief

2 terms

patent infringement lawsuit regulatory

"filed a patent infringement lawsuit against DeGen Medical, Inc."

A patent infringement lawsuit is a court case in which the holder of a patent claims that another party has made, used, sold, or imported a product or process that copies the patent’s protected invention without permission, and asks for remedies such as money damages or a court order to stop the activity. It matters to investors because the outcome can change a company’s ability to sell products, add unexpected costs or liabilities, or alter competitive position—similar to a dispute over who has the exclusive right to use a recipe in a restaurant.

injunctive relief regulatory

"Carlsmed is seeking injunctive relief and damages for infringement."

A court-ordered instruction requiring a person or company to do or stop doing a specific action to prevent harm or preserve a situation. For investors, injunctive relief can immediately alter a business’s operations, block sales or product use, or preserve assets—like a referee pausing play to prevent unfair advantage—so it can swiftly affect revenue, legal exposure and share value while longer legal battles continue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division.

The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking injunctive relief and damages for infringement.

“Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and bringing value to patients, surgeons, and payors every day. We are committed to protecting the intellectual property that supports our patient-centric innovation, which remains at the forefront of the industry,” said Mike Cordonnier, Chairman and CEO of Carlsmed.

About Carlsmed, Inc.

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects, including statements about Carlsmed’s ability to scale its business and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations
IR@Carlsmed.com

Media
media@Carlsmed.com